Transcenta Holding Limited
創勝集團醫藥有限公司
(registered by way of continuation in the Cayman Islands with limited liability)
(Stock Code: 6628)

VOLUNTARY ANNOUNCEMENT

TRANSCENTA PRESENTS UPDATED EFFICACY DATA FROM THE PHASE I/II TRANSTAR102 TRIAL OF OSEMITAMAB PLUS NIVOLUMAB AND CAPOX IN FIRST-LINE G/GEJ CANCER AT ESMO ASIA

- *Data showed encouraging results in patients with higher CLDN18.2 expression, regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 months.*

This announcement is made by Transcenta Holding Limited (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update. Capitalized terms used herein but not otherwise defined shall have the same meaning ascribed thereto in the prospectus of the Company dated September 14, 2021.

The board of directors of the Company (the "**Board**") is pleased to announce updated efficacy analysis of Cohort G by CLDN18.2 and PD-L1 expression from the phase I/II Transtar102 trial of osemitamab plus nivolumab and CAPOX in first-line Gastric/Gastroesophageal Junction (G/GEJ) cancer. The new findings were showcased in a poster presentation (Abstract #299P) at the ESMO Asia Congress 2025 in Singapore.

This new analysis reinforces the encouraging clinical benefit of the osemitamab triple combination regimen in the ongoing study. In the 26 patients with CLDN18.2 expression ≥40%, ≥2+ and known PD-L1 CPS, the median PFS reached 16.6 months, with an ORR of 68% and a median DoR of 18 months at a 25.8-month median follow-up. Notably, better PFS outcomes were observed in patients with higher CLDN18.2 expression compared to lower CLDN18.2 expressors in both PD-L1 CPS <1 and ≥1 subgroups, which indicated the potential treatment benefit of osemitamab is consistent regardless of PD-L1 expression.

The safety profile was similar to that previously presented at ASCO 2025.

"The exploratory efficacy analysis continues to show promising clinical benefit with osemitamab when combined with standard-of-care therapy," said Professor Lin Shen, Director, Department of Gastrointestinal Oncology and Phase I Clinical Trial Center at Peking University Cancer Hospital; and Principal Investigator of the trial. "The consistency of benefit across different PD-L1 subgroups is particularly noteworthy and suggests that this regimen may offer meaningful improvement for a broad population of patients with advanced G/GEJ cancer."

"We are encouraged to see the continued strength of the clinical signals in this study, which reinforce the potential of osemitamab to deliver meaningful benefit to patients in need of more effective treatment options," said Dr. Charlie Qi, Executive Vice President, Head of Global Clinical Development at the Company. "Further, these updated data continue to demonstrate that the combination of osemitamab with nivolumab and CAPOX is safe and well tolerated as a first-line regimen for patients with advanced G/GEJ cancer."

About Osemitamab

Osemitamab is a high affinity humanized anti-CLDN18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity ("**ADCC**"). It has shown potent anti-tumor activities in tumor xenograft models. Osemitamab is the second CLDN18.2 targeting antibody being developed globally. Osemitamab was generated using the Company's Immune Tolerance Breaking Technology (IMTB) platform. Osemitamab kills CLDN18.2 expressing tumor cells by mechanisms of ADCC. Leveraging advanced bioprocessing technology, the fucose content of osemitamab was significantly reduced during the production, which further enhanced NK cells mediated ADCC activity of osemitamab. Osemitamab has been granted Orphan Drug Designation in the U.S. by FDA for the treatment of patients with gastric or gastroesophageal junction (G/GEJ) and pancreatic cancer.

Cautionary statement: We cannot guarantee that we will be able to develop, or ultimately market Osemitamab (TST00l) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Transcenta Holding Limited
Xueming Qian
Executive Director, Chairman and Chief Executive Officer

Hong Kong, December 5, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director, chairman and chief executive officer, Dr. Li Xu as non-executive Director and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive Directors.